Intervención tricuspídea heterotópica: Resultados de TricValve a un año

Heterotopic Tricuspid Intervention: TricValve One-Year Outcomes

Severe tricuspid regurgitation (TR) presents a reserved prognosis when not treated in time, seeing as systemic venous congestion might significantly limit quality of life in these patients. For many years it was thought diuretic therapy was the only option to treat these patients, since the surgical alternative offered suboptimal results and many patients were deemed<a href="https://solaci.org/en/2023/12/11/heterotopic-tricuspid-intervention-tricvalve-one-year-outcomes/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Cilostazol in Diabetic Patients with Endovascular Peripheral Revascularization: One Step Beyond Symptom Improvement

In patients with peripheral vascular disease (PVD), the presence of diabetes has been significantly associated with increased failure of critical lower limb ischemia (CLI) treatment, and higher incidence of amputation. This relationship has been attributed mainly to comorbidities and patient characteristics, concomitant peripheral neuropathy and marked microvascular alteration. Also, a high proportion of these patients<a href="https://solaci.org/en/2023/11/24/cilostazol-in-diabetic-patients-with-endovascular-peripheral-revascularization-one-step-beyond-symptom-improvement/" title="Read more" >...</a>

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Stentless Strategy in ACS: Perfusion and Drug Coated Balloons

The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding.  However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>

Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as we know, is associated with coronary artery disease (CAD) approximately in 50% of cases. In high risk surgical patients, this calls for procedures such as percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR).   PCI with ventricular<a href="https://solaci.org/en/2023/11/08/impella-in-high-risk-coronary-angioplasty-before-tavr/" title="Read more" >...</a>

TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications.  The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve<a href="https://solaci.org/en/2023/10/31/tct-2023-triluminate-trial-health-status-after-triclip/" title="Read more" >...</a>

TCT 2023 | EXPAND G4

The EXPAND G4 is a prospective multicenter single arm study on real life patients.  It included a total 1,164 patients with primary (PMR) and secondary (SMR) mitral valve regurgitation treated with MitraClip G4. Research was carried out at multiple locations across US, Europe, the Middle East and Japan.  Key outcomes assessed aspects such as all-cause<a href="https://solaci.org/en/2023/10/30/tct-2023-expand-g4/" title="Read more" >...</a>

ESC 2023 | BUDAPEST CRT Upgrade trial

Approximately 1 million pacemakers (PM) or Implantable cardioverter-defibrillators (ICDs) are placed every year around the world, and it has been observed that 30% of these cases present left ventricular dysfunction, mainly systolic. This dysfunction is attributed to PM induced right ventricle dyssynchrony, which in time leads to hospitalization for cardiac failure and increased clinical adverse<a href="https://solaci.org/en/2023/08/29/esc-2023-budapest-crt-upgrade-trial-2/" title="Read more" >...</a>

Degenerative Mitral Regurgitation: Impact on Post-Procedural Gradient

Primary or degenerative mitral regurgitation (MR) occurs frequently. Even though surgery continues to be the standard treatment at present, it remains risky for one group of patients, which makes edge-to-edge mitral valve repair (MV-TEER) a viable alternative.  We are well aware that moderate to severe MR is associated with worse prognosis. However, post procedural mean<a href="https://solaci.org/en/2023/08/23/degenerative-mitral-regurgitation-impact-on-post-procedural-gradient/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

Relationship between Distal Vessel Quality and Outcomes in the Treatment of Chronic Total Occlusions

Percutaneous treatment of chronic total occlusions has increase, and has become a a more habitual therapeutic challenge. However, there is limited information on distal vessel quality and its association with outcomes and techniques. This variable appears to be excluded form CTO scores, except for the RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce, the<a href="https://solaci.org/en/2023/07/06/relationship-between-distal-vessel-quality-and-outcomes-in-the-treatment-of-chronic-total-occlusions/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Transcatheter Mitral Valve Replacement vs. Medical Therapy

Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for heart failure and higher mortality.  Transcatheter edge-to-edge repair (TEER), together with guideline-directed medical therapy (GDMT) has been shown beneficial in high risk patients, according to the COAPT study. However, there is a significant group of patients that make<a href="https://solaci.org/en/2023/07/04/transcatheter-mitral-valve-replacement-vs-medical-therapy/" title="Read more" >...</a>